Search
                    Hereditary Angioedema (HAE) Clinical Trials
A listing of 5  Hereditary Angioedema (HAE)  clinical trials  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 5 of 5
        
        
    
                There are currently 5 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. The states with the highest number of trials for Hereditary Angioedema (HAE) participants are California, Ohio, Texas and Pennsylvania.
            
                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    A Phase 2 in Adult Subjects With Hereditary Angioedema
                                
            
            
        Recruiting
                            
            
                A Phase 2 in Adult Subjects with Hereditary Angioedema             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 70 years
            Trial Updated:
                08/03/2025
            
            Locations: Raffi Tachdjian, MD Inc, Santa Monica, California  +18 locations         
        
        
            Conditions: Hereditary Angioedema (HAE)
        
            
        
    
                
                                    Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
                                
            
            
        Recruiting
                            
            
                This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.             
        
        
    Gender:
                ALL
            Ages:
                12 years and above
            Trial Updated:
                07/28/2025
            
            Locations: Study Site, Little Rock, Arkansas  +51 locations         
        
        
            Conditions: Hereditary Angioedema (HAE)
        
            
        
    
                
                                    Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
                                
            
            
        Recruiting
                            
            
                This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema             
        
        
    Gender:
                ALL
            Ages:
                12 years and above
            Trial Updated:
                07/28/2025
            
            Locations: Study Site, Santa Monica, California  +16 locations         
        
        
            Conditions: Hereditary Angioedema (HAE)
        
            
        
    
                
                                    A Study of Navenibart in Participants With Hereditary Angioedema
                                
            
            
        Recruiting
                            
            
                This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.             
        
        
    Gender:
                ALL
            Ages:
                12 years and above
            Trial Updated:
                06/23/2025
            
            Locations: Site 9, Birmingham, Alabama  +13 locations         
        
        
            Conditions: Hereditary Angioedema (HAE)
        
            
        
    
                
                                    Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
                                
            
            
        Recruiting
                            
            
                To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                06/23/2025
            
            Locations: Institute For Asthma & Allergy, Wheaton, Maryland         
        
        
            Conditions: Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency
        
            
        
    1 - 5 of 5
            
            
        